Published in J Invest Dermatol on January 22, 2013
Melanoma: clinical features and genomic insights. Cold Spring Harb Perspect Med (2014) 0.77
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med (2014) 5.43
Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. J Am Acad Dermatol (2003) 4.15
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol (2012) 3.71
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res (2004) 2.82
The immune score as a new possible approach for the classification of cancer. J Transl Med (2012) 2.79
BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol (2012) 2.41
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol (2012) 2.03
The role of BRAF V600 mutation in melanoma. J Transl Med (2012) 2.00
Filling-port complications in Becker expanders. Plast Reconstr Surg (2012) 1.96
Main roads to melanoma. J Transl Med (2009) 1.67
Patterns of detection of superficial spreading and nodular-type melanoma: a multicenter Italian study. Dermatol Surg (2004) 1.57
EGFR mutational status in penile cancer. Expert Opin Ther Targets (2013) 1.57
Dermoscopic evaluation of amelanotic and hypomelanotic melanoma. Arch Dermatol (2008) 1.51
Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res (2013) 1.48
Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J Clin Oncol (2010) 1.45
Clinical genetic testing for familial melanoma in Italy: a cooperative study. J Am Acad Dermatol (2009) 1.45
Toxic epidermal necrolysis (Lyell's disease). Burns (2009) 1.44
Distribution and significance of 14-3-3sigma, a novel myoepithelial marker, in normal, benign, and malignant breast tissue. J Pathol (2004) 1.41
HCV-related hepatocellular carcinoma: From chronic inflammation to cancer. Clin Immunol (2009) 1.35
The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. J Transl Med (2013) 1.31
X-inactivation patch size in human female tissue confounds the assessment of tumor clonality. Proc Natl Acad Sci U S A (2003) 1.30
Dermatologist detection and skin self-examination are associated with thinner melanomas: results from a survey of the Italian Multidisciplinary Group on Melanoma. Arch Dermatol (2003) 1.27
Prune cAMP phosphodiesterase binds nm23-H1 and promotes cancer metastasis. Cancer Cell (2004) 1.27
Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother (2014) 1.23
BRCA1 and BRCA2 point mutations and large rearrangements in breast and ovarian cancer families in Northern Poland. Oncol Rep (2008) 1.16
Human melanoma metastases express functional CXCR4. Clin Cancer Res (2006) 1.15
Accuracy in melanoma detection: a 10-year multicenter survey. J Am Acad Dermatol (2011) 1.15
NF-κB as potential target in the treatment of melanoma. J Transl Med (2012) 1.14
MC1R variants increased the risk of sporadic cutaneous melanoma in darker-pigmented Caucasians: a pooled-analysis from the M-SKIP project. Int J Cancer (2014) 1.10
Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): a case report. J Med Case Rep (2012) 1.09
Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients. J Transl Med (2013) 1.03
Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010". J Transl Med (2011) 1.02
Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy. BMC Cancer (2009) 1.02
Dermoscopic evaluation of nodular melanoma. JAMA Dermatol (2013) 0.99
Antiproliferative and pro-apoptotic activity of eugenol-related biphenyls on malignant melanoma cells. Mol Cancer (2007) 0.98
Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction. J Clin Oncol (2003) 0.97
Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases. Melanoma Res (2005) 0.97
Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia. J Transl Med (2012) 0.97
Spectrum and prevalence of BRCA1 and BRCA2 germline mutations in Sardinian patients with breast carcinoma through hospital-based screening. Cancer (2005) 0.97
Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1. J Immunotoxicol (2012) 0.96
Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South Italy. Eur J Cancer (2006) 0.96
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment. J Transl Med (2014) 0.95
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". J Transl Med (2013) 0.95
Increased HOX C13 expression in metastatic melanoma progression. J Transl Med (2012) 0.95
Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment. J Transl Med (2010) 0.93
NEMO-binding domain peptide inhibits proliferation of human melanoma cells. Cancer Lett (2008) 0.93
Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial. J Clin Oncol (2013) 0.92
Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma. J Transl Med (2013) 0.92
A variant of lymphomatoid papulosis simulating primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma. Description of 9 cases. Am J Surg Pathol (2010) 0.91
CXC chemokine receptor 4 is expressed in uveal malignant melanoma and correlates with the epithelioid-mixed cell type. Cancer Immunol Immunother (2007) 0.91
Negative pigment network: an additional dermoscopic feature for the diagnosis of melanoma. J Am Acad Dermatol (2012) 0.91
Expression of the anti-apoptotic protein BAG3 in human melanomas. J Invest Dermatol (2011) 0.91
Overexpression of h-prune in breast cancer is correlated with advanced disease status. Clin Cancer Res (2005) 0.90
A role of BRCA1 and BRCA2 germline mutations in breast cancer susceptibility within Sardinian population. BMC Cancer (2009) 0.90
CASC2a gene is down-regulated in endometrial cancer. Anticancer Res (2007) 0.90
High-resolution methylation analysis of the hMLH1 promoter in sporadic endometrial and colorectal carcinomas. Cancer (2003) 0.89
Synchronous interdigitating dendritic cell sarcoma and B-cell small lymphocytic lymphoma in a lymph node. Arch Pathol Lab Med (2006) 0.89
Presence of Jaagsiekte sheep retrovirus in tissue sections from human bronchioloalveolar carcinoma depends on patients' geographical origin. Hum Pathol (2008) 0.89
Epidemiology of thyroid cancer in an area of epidemic thyroid goiter. J Cancer Epidemiol (2013) 0.88